ERG and prostate cancer: PARP inhibitors, a direct ERG binding small molecule (YK-4-279), a DNA-binding inhibitor targeting ETS consensus sites (DB1255), and a drug that enhances ERG ubiquitination (WP1130) are all promising compounds for prostate cancer [151,152,153,154].